Abstract:Background Phosphoinositide-3-kinase Delta (PI3K delta) plays a key role in B-cell signal transduction and inhibition of PI3K delta is confirmed to have clinical benefit in certain types of activation of B-cell malignancies. Virtual screening techniques have been used to discover new molecules for developing novel PI3K delta inhibitors with little side effects. Method: Computer aided drug design method were used to rapidly screen optimal PI3K delta inhibitors from the Asinex database. Virtual screening based molecular docking was performed to find novel and potential lead compound targeting PI3K delta, at first. Subsequently, drug likeness studies were carried out on the retrieved hits to evaluate and analyze their drug like properties such as absorption, distribution, metabolism, excretion, and toxicity (ADMET) for toxicity prediction. Three least toxic compounds were selected for the molecular dynamics (MD) simulations for 30 ns in order to validate its stability inside the active site of PI3K delta receptor. Results: Based on the present in silico analysis, two molecules have been identified which occupied the same binding pocket confirming the selection of active site. ASN 16296138 (Glide score: - 12.175 kcal/mol, cdocker binding energy: - 42.975 kcal/mol and Delta G(bind) value: - 90.457 kcal/mol) and HAS 00227397 (Glide score: - 10.988 kcal/mol, cdocker binding energy: - 39.3376 kcal/mol and Delta G(bind) value: - 81.953 kcal/mol) showed docking affinities comparatively much stronger than those of already reported known inhibitors against PI3K delta. These two ligand's behaviors also showed consistency during the simulation of protein-ligand complexes for 30000 ps respectively, which is indicative of its stability in the receptor pocket. Conclusion: Compound ASN 16296138 and BAS 00227397 are potential candidates for experimental validation of biological activity against PI3K delta in future drug discovery studies. This study smoothes the path for the development of novel leads with improved binding properties, high drug likeness, and low toxicity to humans for the treatment of cancer.

Theoretical Studies on Beta and Delta Isoform-Specific Binding Mechanisms of Phosphoinositide 3-Kinase Inhibitors.

Understanding the Selectivity of Inhibitors Toward PI4KIIIα and PI4KIIIβ Based Molecular Modeling

Development of small-molecule inhibitors that target PI3Kβ

Development of small-molecule inhibitors that target PI3K13

Exploring the Selective Mechanism of Inhibitors Towards Different Subtypes of Class I PI3K

Class I phospho-inositide-3-kinases (PI3Ks) isoform-specific inhibition study by the combination of docking and molecular dynamics simulation.

Exploring Binding Preference of Three Drugs Targeting Pi3Kγ Via Energetic, Pharmacophore and Dissociation Pathway Analyses

Study on improving the selectivity of compounds that inhibit two PI3Ks (gamma and delta)

Characterization of molecular recognition of Phosphoinositide-3-kinase α inhibitor through molecular dynamics simulation

Targeting Phosphatidylinositol 3‐kinase Gamma (pi3kγ): Discovery and Development of Its Selective Inhibitors

Exploring PI3Kγ binding preference with Eganelisib, Duvelisib, and Idelalisib via energetic, pharmacophore and dissociation pathway analyses

Identification of Novel PI3Kδ Inhibitors by Docking, ADMET Prediction and Molecular Dynamics Simulations.

Action Mechanisms and Structure–activity Relationships of PI3Kγ Inhibitors on the Enzyme: a Molecular Modeling Study

PI3K Inhibitors for Cancer Therapy: What Has Been Achieved So Far?

Crystal Structures of PI3Kα Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design.

Small Molecules Targeting Phosphoinositide 3-Kinases

Study on Selectivity of Inhibitor BD2 for PKA over PKC beta II

Class IA PI3K isoforms lead to differential signalling downstream of PKB/Akt

A Selectivity Study On Mtor/Pi3k Alpha Inhibitors By Homology Modeling And 3d-Qsar

Development of PI3Kγ selective inhibitors: the strategies and application

Developing new PI3Kγ inhibitors by combining pharmacophore modeling, molecular dynamic simulation, molecular docking, fragment-based drug design, and virtual screening